Evidence map›Paper›PMID 42837045›Full record

ReviewJournal of neuro-oncology2026

Spinal ependymoma: a comprehensive review of molecular classification, management guidelines, and clinical outcomes with a focus on the pediatric population (Part III of ependymomas across compartments).

Anthony M Price, Nathan S Fredricks, George Koutsouras, Frederic A Vallejo, Christopher Bonfield, Devang J Pastakia, Leo Y Luo, Frederick Boop, Vijay Ramaswamy, Michael C Dewan

Abstract readReview
In one paragraph

Review in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Anthony M PriceDepartment of Neurological Surgery, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID https://orcid.org/0000-0002-8927-3384
Nathan S FredricksJohn Sealy School of Medicine, The University of Texas Medical Branch at Galveston, Galveston, TX, USA.
George KoutsourasDepartment of Neurological Surgery, Vanderbilt University Medical Center, Nashville, TN, USA.
Frederic A VallejoDepartment of Neurological Surgery, Vanderbilt University Medical Center, Nashville, TN, USA.
Christopher BonfieldDepartment of Neurological Surgery, Vanderbilt University Medical Center, Nashville, TN, USA.
Devang J PastakiaDepartment of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, USA.
Leo Y LuoDepartment of Radiation Oncology, Vanderbilt University Medical Center, Nashville, TN, USA.
Frederick BoopDepartment of Neurosurgery, University of Tennessee Health Science Center, Memphis, TN, USA.
Vijay RamaswamyDivision of Haematology/Oncology, The Hospital for Sick Children, Toronto, ON, Canada.
Michael C DewanDepartment of Neurological Surgery, Vanderbilt University Medical Center, Nashville, TN, USA. michael.dewan@vumc.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeSpinal ependymomas are rare tumors of the central nervous system characterized by distinct anatomical, histological, and molecular subtypes. This review aims to synthesize current evidence regarding the presentation, diagnosis, surgical management, adjuvant therapy, and outcomes of spinal ependymomas, with a focus on the pediatric population.

methodsWe conducted a narrative review of contemporary literature, consensus recommendations, and relevant treatment-related molecular classifications. Key topics included preoperative evaluation, neuraxis imaging, intraoperative strategies, extent of resection, histopathologic and molecular risk stratification, adjuvant radiotherapy and chemotherapy, recurrence patterns, and long-term surveillance. Representative clinical cases illustrating the surgical management of intramedullary spinal ependymomas and myxopapillary ependymomas are provided in the supplementary material.

resultsSpinal ependymomas encompass spinal ependymoma, spinal ependymoma with MYCN amplification, spinal subependymoma, and spinal myxopapillary ependymoma. The primary therapeutic goal is maximal safe gross total resection, which is the most consistent modifiable predictor of progression-free survival. Molecular classification enhances risk stratification, especially for the aggressive MYCN-amplified subgroup. However, histologic grade and the extent of resection remain critical to management. Adjuvant radiotherapy is generally recommended for cases involving subtotal resection, grade 3 disease, tumor dissemination, capsular violation in myxopapillary tumors, or high-risk biology. Chemotherapy does not have a well-established role as a first-line treatment. Much of this evidence is extrapolated from adult or mixed-age cohorts, however, and pediatric-specific data remain limited across nearly every management domain, a gap we characterize systematically.

conclusionManagement of spinal ependymomas is centered around surgery and adapted to individual risk factors. Overall survival is generally favorable for spinal ependymomas, but recurrence risk remains substantial and varies by extent of resection and molecular subtype. Lifelong surveillance is crucial, as both local recurrence and craniospinal dissemination may occur long after treatment.

Indexed as

EpendymomaPractice Guidelines as TopicSpinal Cord NeoplasmsChildHumansEpendymomaIntramedullary tumorLaminoplastyMYCN amplificationMyxopapillary ependymomaPediatric spinal ependymomaSpinal ependymoma

Identifiers

PMID42837045
PMCPMC13642508

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.